Today, Novavax, Inc. announced that it had signed a contract with the European Commission (EC) to purchase up to 200 million doses of NVX-CoV2373.
Novavax is a biotechnology firm developing next-gen vaccines for serious infectious diseases. NVXCoV2373 is a recombinant nano-particle protein-based COVID-19 vaccination that includes a MatrixM™ supplement.
The contract covers purchasing up to 100 million doses of the vaccine, with another 100 million doses by 2023.
Novavax is completing the rolling of NVX-CoV2373 to the European Medicines Agency
(EMA) in the 3rd quarter of 2021 and is expected to begin supplying initial capacity after approval.
“We thank the European Commission for their partnership in this important step to expand
vaccine options for the citizens of Europe and globally as we work to bring the first COVID
19 protein subunit vaccine to the market,” said the President and Chief Executive Officer of Novavax, Stanley C. Erck.
“With clinical data from our trials showing strong efficacy against Variants of Concern and
Variants of Interest, we believe that our vaccine candidate will play a critical role in the
effort to help control the pandemic in the EU and other regions in the world.” He added.
NVX-CoV2373 showed 100% protection against moderate to severe disease and overall
effectiveness of 90.4% in phase 3 clinical trials involving around 30,000 adults in the US and Mexico.
However, In the UK, NVX-CoV2373 showed an overall efficacy of 89.7% and efficacy of over
96% against the original strain of the virus in phase 3 clinical trial with around 15,000 adults.
Ursula von der Leyen, President of the EC, said that as variants spread globally, this new
agreement with a company proven successful is additional protection for the population.
“It further strengthens our broad vaccine portfolio, to the benefit of Europeans and our partners worldwide,” Leyen added.
The global supply chain of Novavax covers over a dozen countries, including facilities
throughout the EU which it plans to supply to eventually.